A new antibacterial drug product (Zerbaxa) has been approved by U.S. Food and Drug Administration (FDA) to treat complicated type of urinary tract (cUTIs) and intra-abdominal infections (cIAIs) in adults.
Zerabex is customarily prescribed in combination with metronidazole to treat c UTIs.
Zerbaxa contain two drug products, ceftolozane which is an antibiotic belongs to cephalosporin class and tazobactum which inhibits beta lectamase enzyme, thus prevents degradation of ceftozolane.
A status of Qualified Infectious Drug Product (QIDP) has been granted by FDA to Zerbaxa as it is effective against fetal infections of either bacterial or fungal origin.
Safety and Effectiveness:
The drug was found safer and clinically effective after investigating a clinical study that was conducted on 979 adults. They were randomly given Zerbexa plus metronidazole or meropenam. The results of this study confirmed the effectiveness of Zerabex plus metronidazole in cUTIs.
Most widespread side effects that were found during this clinical trial were;
Zerbexa is being marketed by Cubist Pharmaceuticals, based in Lexington, Massachusetts.
Copyright 2012 Medimoon.com. All rights reserved. No part of this site can be reproduced without our written permission.